Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3046 for:    "Myeloid Leukemia"

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03760523
Recruitment Status : Recruiting
First Posted : November 30, 2018
Last Update Posted : April 10, 2019
Sponsor:
Collaborator:
Minneamrita Therapeutics LLC
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

Brief Summary:
This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Minnelide Phase 1

Detailed Description:
This phase 1 dose escalation clinical trial will establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Minnelide as single-agent in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients who are ineligible to receive intensive chemotherapy. The oral formulation of Minnelide will be used. Minnelide is a prodrug of triptolide (a potent heat shock protein (HSP) 70 inhibitor) with promising preclinical activity in AML.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Actual Study Start Date : April 8, 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Experimental: Minnelide Dose Escalation
A 3+3 design will be used. The first 3 patients will be treated at dose level 1. If none experience a Dose Limiting Toxicity (DLT), the next 3 patients will be treated at dose level 2. If a DLT is observed in 1 out of 3 patients at dose level 1, up to an 3 more patients will be enrolled and treated at that dose level. If 2 patients at dose level have DLTs, dosing will be lowered to dose level -1 (.5 mg daily, taken orally). If 2 or more of the up to 6 patients at any dose level have DLTs, the preceding dose will be declared the Maximum Tolerated Dose (MTD). If more than 1 DLT occurs at Dose Level -1, the investigators will consider stopping the study. Once the MTD has been established, an additional 10 patients will be enrolled at this level to better characterize safety and tolerability.
Drug: Minnelide
Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) of Minnelide [ Time Frame: Up to 28 days for each dosing cohort ]
    MTD will be determined by testing increasing doses up to 1.25 mg daily. MTD reflects highest dose of drug that did not cause a Dose Limiting Toxicity (DLT).

  2. Number of Participants Who Experience Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 28 days for each dosing cohort ]
    A DLT is any Grade 3 or 4 drug-related non-hematologic toxicity, with some exceptions per protocol.


Secondary Outcome Measures :
  1. Complete Response (CR) [ Time Frame: Up to 12 months ]
    Participants who experience Complete Response (CR) and Complete Response with Incomplete Blood Count Recovery (CRi) rate as defined by 2003 International Working Group (IWG) for AML.

  2. Overall Response Rate (ORR) [ Time Frame: Up to 12 months ]
    Overall Response Rate is defined as CR + CRi + partial response (PR) as defined by 2003 IWG criteria for AML.

  3. Relapse Free Survival (RFS) [ Time Frame: Up to 18 months ]
    RFS is defined as time interval between achievement of CR to time of relapse.

  4. Overall Survival (OS) [ Time Frame: Up to 12 months ]
    OS defined as time interval from time of enrollment onto the clinical trial to death from any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults ages 18 years or older.
  • Participant must have relapsed or refractory acute myeloid leukemia (AML) (excluding acute promyelocytic leukemia).
  • Relapsed patients must have received at least 1 induction chemotherapy regimen or two cycles of a hypomethylating agent and achieved a Complete Response (CR), followed by relapse of disease.
  • Refractory patients must have received at least 1 induction chemotherapy regimen or two cycles of hypomethylating agent without achieving a CR.
  • Eastern Cooperative Oncology Group (ECOG) performance status <2.
  • Participants must have acceptable organ function.
  • Be able and willing to adhere to the study visit schedule and other protocol requirements.
  • Must be able to swallow capsules and have no evidence of GI tract abnormality that would alter the absorption of oral medications.
  • The effects of Minnelide on the developing human fetus are unknown. For this reason, women of child-bearing potential must have a negative serum or urine pregnancy test within 24 hours prior to beginning study treatment.
  • Participants of childbearing potential must practice contraception. Females of childbearing potential: Recommendation is for 2 effective contraceptive methods during the study. Male participants with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Minnelide, breastfeeding mothers must agree to discontinue nursing if the mother is treated with Minnelide.
  • Provision of signed and dated informed consent document
  • Patients with prior allogeneic stem cell transplant who experience relapse of AML are eligible if they are off of immunosuppressive therapy and without any evidence of graft-versus-host disease (GVHD)

Exclusion Criteria:

  • Participants may not have received any therapy with any investigational products, systemic anti-neoplastic therapy, or radiotherapy within 14 days prior to Cycle 1 Day 1. Patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea during protocol treatment.
  • Candidates for standard and/or potentially curative treatments.
  • Major surgery within 28 days prior to Cycle 1 Day 1.
  • New York Heart Association Class III or IV heart failure, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on an electrocardiogram (EKG)
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • Known, active HIV, Hepatitis A, B or C infection (prior Hepatitis C infection that has been treated and determined to be cured is allowed)
  • Symptomatic central nervous system (CNS) involvement with leukemia
  • A concurrent second active and non-stable malignancy with the exception of non-melanoma skin cancer or carcinoma in-situ.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03760523


Locations
Layout table for location information
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
Contact: Anthony McLaughlin    813-745-5941    Anthony.McLaughlin@moffitt.org   
Principal Investigator: Chetasi Talati, MD         
Principal Investigator: Kendra Sweet, MD         
Sub-Investigator: David Sallman, MD         
Sub-Investigator: Jeffrey Lancet, MD         
Sub-Investigator: Rami Komrokji, MD         
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Minneamrita Therapeutics LLC
Investigators
Layout table for investigator information
Principal Investigator: Chetasi Talati, MD H. Lee Moffitt Cancer Center and Research Institute

Additional Information:
Layout table for additonal information
Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT03760523     History of Changes
Other Study ID Numbers: MCC-19742
First Posted: November 30, 2018    Key Record Dates
Last Update Posted: April 10, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
leukemia
myeloid leukemia

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms